New hope for back pain: higher dose of secukinumab tested in chinese ankylosing spondylitis patients

NCT ID NCT05303285

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a higher dose (300 mg) of the drug secukinumab (Cosentyx) can safely and effectively reduce symptoms in Chinese adults with active ankylosing spondylitis who have not gotten relief from at least two NSAIDs. One hundred participants will receive either 300 mg or 150 mg of secukinumab as an injection. The main goal is to see if more patients achieve a 40% improvement in disease activity after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (Cosentyx), a biologic drug given as an injection
What this could lead to: If successful, this could confirm that a higher dose of secukinumab (300 mg) is safe and effective for Chinese patients with ankylosing spondylitis who have not responded to standard treatments.
What could go wrong: This is a phase 4 study with a relatively small number of participants (100). The results may not apply to all patients, and there is always a risk of side effects such as infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS (AS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS (AS)

Contacts and locations

Locations

Department of RheumatologyTongji Hospital
RECRUITING

Wuhan, Hubei, 430030, China
Tongji Hospital
RECRUITING

Wuhan, Hubei, 430030, China
Tongji Hospital
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.